Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 2Glioblastoma 2

Interventions

Temozolomide 159Bevacizumab 69Radiotherapy 68Magnetic Resonance Spectroscopy 68Irinotecan 31Surgical Procedures, Operative 27Radiation 24Carboplatin 23Specimen Handling 20Carmustine 20Blood Specimen Collection 20Nivolumab 19Aminolevulinic Acid 18Biopsy 17Lomustine 15pembrolizumab 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12fluorodopa F 18 12X-Rays 12Radiosurgery 12Erlotinib Hydrochloride 12Topotecan 11Everolimus 11Magnetic Resonance Imaging 10IL13-PE38 10dabrafenib 9Etoposide 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioma × LY-2157299 × CNS × Clear all
NCT01682187 2024-11-07

A Dose-Escalation Study in Participants With Recurrent Malignant Glioma

Eli Lilly and Company

Phase 1 Completed
66 enrolled
CNS

Glioma

NCT01220271 2017-02-16

A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

Eli Lilly and Company

Phase 1/2 Completed
75 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡